Literature DB >> 19233564

Upregulation of IL-6, IL-8 and CCL2 gene expression after acute inflammation: Correlation to clinical pain.

Xiao-Min Wang1, May Hamza, Tian-Xia Wu, Raymond A Dionne.   

Abstract

Tissue injury initiates a cascade of inflammatory mediators and hyperalgesic substances including prostaglandins, cytokines and chemokines. Using microarray and qRT-PCR gene expression analyses, the present study evaluated changes in gene expression of a cascade of cytokines following acute inflammation and the correlation between the changes in the gene expression level and pain intensity in the oral surgery model of tissue injury and acute pain. Tissue injury resulted in a significant upregulation in the gene expression of interleukin-6 (IL-6; 63.3-fold), IL-8 (8.1-fold), chemokine (C-C motif) ligand 2 (CCL2; 8.9-fold), chemokine (C-X-C motif) ligand 1 (CXCL1; 30.5-fold), chemokine (C-X-C motif) ligand 2 (CXCL2; 26-fold) and annexin A1 (ANXA1; 12-fold). The upregulation of IL-6 gene expression was significantly correlated to the upregulation of IL-8, CCL2, CXCL1 and CXCL2 gene expression. Interestingly, the tissue injury-induced upregulation of IL-6, IL-8 and CCL2 gene expression, was positively correlated to pain intensity at 3h post-surgery, the onset of acute inflammatory pain. However, ketorolac treatment did not have a significant effect on the gene expression of IL-6, IL-8, CCL2, CXCL2 and ANXA1 at the same time point of acute inflammation. These results demonstrate that the upregulation of IL-6, IL-8 and CCL2 gene expression contributes to the development of acute inflammation and inflammatory pain. The lack of effect of ketorolac on the expression of these gene products may be related to the ceiling analgesic effects of non-steroidal anti-inflammatory drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19233564      PMCID: PMC3513699          DOI: 10.1016/j.pain.2009.02.001

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   7.926


  75 in total

1.  The angiogenic factor Cyr61 activates a genetic program for wound healing in human skin fibroblasts.

Authors:  C C Chen; F E Mo; L F Lau
Journal:  J Biol Chem       Date:  2001-10-02       Impact factor: 5.157

2.  Discrete roles of cytokines, TNF-alpha, IL-1, IL-6 in tumor promotion and cell transformation.

Authors:  M Suganuma; S Okabe; M Kurusu; N Iida; S Ohshima; Y Saeki; T Kishimoto; H Fujiki
Journal:  Int J Oncol       Date:  2002-01       Impact factor: 5.650

3.  Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia.

Authors:  U K Munshi; J O Niu; M M Siddiq; L A Parton
Journal:  Pediatr Pulmonol       Date:  1997-11

4.  The IL-6-soluble IL-6Ralpha autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin.

Authors:  V Marin; F A Montero-Julian; S Grès; V Boulay; P Bongrand; C Farnarier; G Kaplanski
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

5.  Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation.

Authors:  S M Hurst; T S Wilkinson; R M McLoughlin; S Jones; S Horiuchi; N Yamamoto; S Rose-John; G M Fuller; N Topley; S A Jones
Journal:  Immunity       Date:  2001-06       Impact factor: 31.745

6.  The angiogenic factor cysteine-rich 61 (CYR61, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin alpha(6)beta(1) and cell surface heparan sulfate proteoglycans.

Authors:  Tatiana M Grzeszkiewicz; Volkhard Lindner; Ningyu Chen; Stephen C-T Lam; Lester F Lau
Journal:  Endocrinology       Date:  2002-04       Impact factor: 4.736

7.  Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms.

Authors:  Rachel M McLoughlin; Suzanne M Hurst; Mari A Nowell; Dean A Harris; Sankichi Horiuchi; Llinos W Morgan; Thomas S Wilkinson; Naoki Yamamoto; Nicholas Topley; Simon A Jones
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

8.  Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor alpha-mediated CINC-1 release in rat liver cells: novel actions of lipoxin A4 (LXA4) and ASA-triggered 15-epi-LXA4.

Authors:  Anna Planagumà; Esther Titos; Marta López-Parra; Joan Gaya; Gloria Pueyo; Vicente Arroyo; Joan Clària
Journal:  FASEB J       Date:  2002-10-04       Impact factor: 5.191

9.  Synergy between tumour necrosis factor alpha and interleukin-1 in the induction of polymorphonuclear leukocyte migration during inflammation.

Authors:  Z Wankowicz; P Megyeri; A Issekutz
Journal:  J Leukoc Biol       Date:  1988-04       Impact factor: 4.962

10.  Human peritoneal mesothelial cells synthesize interleukin-8. Synergistic induction by interleukin-1 beta and tumor necrosis factor-alpha.

Authors:  N Topley; Z Brown; A Jörres; J Westwick; M Davies; G A Coles; J D Williams
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

View more
  51 in total

1.  Pro-inflammatory cytokines expression increases following low- and high-magnitude cyclic loading of lumbar ligaments.

Authors:  Peter D'Ambrosia; Karen King; Bradley Davidson; Bing He Zhou; Yun Lu; Moshe Solomonow
Journal:  Eur Spine J       Date:  2010-03-25       Impact factor: 3.134

Review 2.  Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy.

Authors:  Xiao-Min Wang; Tanya J Lehky; Joanna M Brell; Susan G Dorsey
Journal:  Cytokine       Date:  2012-04-24       Impact factor: 3.861

3.  Stress response and procedural pain in the preterm newborn: the role of pharmacological and non-pharmacological treatments.

Authors:  Eloisa Gitto; Salvatore Pellegrino; Maria Manfrida; Salvatore Aversa; Giuseppe Trimarchi; Ignazio Barberi; Russel J Reiter
Journal:  Eur J Pediatr       Date:  2011-12-30       Impact factor: 3.183

4.  Clinical importance of chemokines and inflammatory cytokines for patient care following percutaneous nephrolithotripsy.

Authors:  Junrong Wang; Wei Wang; Wei Guo; Yanru Ma; Tianhui Ji; Baodi Zhang
Journal:  Exp Ther Med       Date:  2017-12-15       Impact factor: 2.447

5.  Inflammation in the pathogenesis of lyme neuroborreliosis.

Authors:  Geeta Ramesh; Peter J Didier; John D England; Lenay Santana-Gould; Lara A Doyle-Meyers; Dale S Martin; Mary B Jacobs; Mario T Philipp
Journal:  Am J Pathol       Date:  2015-04-16       Impact factor: 4.307

6.  Gene expression in skin, muscle, and dorsal root ganglion after plantar incision in the rat.

Authors:  Christina M Spofford; Timothy J Brennan
Journal:  Anesthesiology       Date:  2012-07       Impact factor: 7.892

7.  CCL2 released at tumoral level contributes to the hyperalgesia evoked by intratibial inoculation of NCTC 2472 but not B16-F10 cells in mice.

Authors:  Marta Pevida; Sara González-Rodríguez; Ana Lastra; Agustín Hidalgo; Luis Menéndez; Ana Baamonde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-09-14       Impact factor: 3.000

8.  Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease.

Authors:  Amalia Enríquez-de-Salamanca; Evangelina Castellanos; Michael E Stern; Itziar Fernández; Ester Carreño; Carmen García-Vázquez; Jose M Herreras; Margarita Calonge
Journal:  Mol Vis       Date:  2010-05-19       Impact factor: 2.367

9.  Kinin B1 receptors contributes to acute pain following minor surgery in humans.

Authors:  May Hamza; Xiao-Min Wang; Albert Adam; Jaime S Brahim; Janet S Rowan; Gilberto N Carmona; Raymond A Dionne
Journal:  Mol Pain       Date:  2010-02-13       Impact factor: 3.395

10.  Acute Low Back Pain: Differential Somatosensory Function and Gene Expression Compared With Healthy No-Pain Controls.

Authors:  Angela R Starkweather; Divya Ramesh; Debra E Lyon; Umaporn Siangphoe; Xioayan Deng; Jamie Sturgill; Amy Heineman; R K Elswick; Susan G Dorsey; Joel Greenspan
Journal:  Clin J Pain       Date:  2016-11       Impact factor: 3.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.